INCY * Stoklara Genel Bakış Bir biyofarmasötik şirketi olan Incyte Corporation, Amerika Birleşik Devletleri'nde ve uluslararası alanda hematoloji/onkoloji, inflamasyon ve otoimmünite alanlarına yönelik terapötiklerin keşfi, geliştirilmesi ve ticarileştirilmesi faaliyetlerini yürütmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Incyte Corporation Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Incyte Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$1,486.00 52 Haftanın En Yüksek Seviyesi US$1,486.00 52 Haftanın En Düşük Seviyesi US$986.00 Beta 0.71 1 Aylık Değişim 0% 3 Aylık Değişim n/a 1 Yıllık Değişim n/a 3 Yıllık Değişim -0.40% 5 Yıllık Değişim 0.81% Halka arzdan bu yana değişim -11.60%
Son Haberler & Güncellemeler
Incyte Corporation to Report Q4, 2024 Results on Feb 10, 2025 Jan 21
Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan 16
Incyte Corporation Announces Retirement of Barry P. Flannelly as Executive Vice President, Effective July 31, 2025 Jan 13
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Insufficient new directors Nov 01 Daha fazla güncelleme görün
Incyte Corporation to Report Q4, 2024 Results on Feb 10, 2025 Jan 21
Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan 16
Incyte Corporation Announces Retirement of Barry P. Flannelly as Executive Vice President, Effective July 31, 2025 Jan 13
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Insufficient new directors Nov 01
Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024 Oct 08
Insufficient new directors Oct 02
Insider recently sold Mex$10m worth of stock Sep 18 Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma Aug 16
Executive VP & Chief Medical Officer recently sold Mex$13m worth of stock Aug 15
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023) Jul 31
Executive VP of Global Medical Affairs recently sold Mex$20m worth of stock Jul 30
Executive VP & GM of North America recently sold Mex$1.5m worth of stock Jul 23
Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024 Jul 10
VP of Finance recently sold Mex$1.1m worth of stock Jun 13
Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders. Jun 01 Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 16
Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 14
Incyte Corporation, Annual General Meeting, Jun 12, 2024 May 01
Incyte Corporation Maintains Earnings Guidance for 2024 Apr 30
Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million. Apr 23
Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024 Apr 12
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS) Mar 11
Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022) Feb 14
Incyte Corporation Provides Earnings Guidance for 2024 Feb 14
New minor risk - Profit margin trend Feb 02
Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024 Jan 24
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Incyte Corporation Provides Earning Guidance for the Full Year 2023 Nov 01 Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo Oct 12
Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023 Oct 11
Incyte Corporation Announces Executive Changes, Effective November 1, 2023 Sep 14
Incyte Corporation Revises Earnings Guidance for the Year 2023 Aug 02
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25 Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023
Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023 May 09
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa Feb 11 Incyte Corporation Provides Earnings Guidance for the Year 2023
Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis Dec 13
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology Dec 06
Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine Oct 20
Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022 Oct 12
Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors Oct 05
Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion. Oct 04
Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement Aug 27
Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022 Aug 03
Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo Jul 19
Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022 Jul 13
FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata Jun 14
Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa) May 21
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 May 12
Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease May 05
Incyte Corporation, Annual General Meeting, Jun 15, 2022 May 02
Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer Apr 23
Incyte Corporation to Report Q1, 2022 Results on May 03, 2022 Apr 13
Incyte Corporation Provides Revenue Guidance for the Full Year 2022 Feb 09
Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo Dec 15 MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020) Nov 04
Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million. Sep 29 Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD) Sep 23
Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults Sep 20
Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation Sep 19
Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Aug 25
Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial Aug 05
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease Jul 15
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jun 26
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis Jun 12
Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease Jun 09
Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL Jun 05
Incyte Corporation Announces Positive Primary Analysis from the Phase 2 Optic Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (Cp-Cml) to Be Presented At the 2021 Asco Annual Meeting May 21
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo May 18
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma May 12
Incyte Corporation Provides Revenue Guidance for the Full Year 2021 May 05
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation Mar 19
Eli Lilly and Company and Incyte Announce Top-Line Results from BRAVE-AA2 Mar 04
Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as Treatment for Patients with Squamous Cell Anal Carcinoma Feb 26
Chairman recently bought Mex$21m worth of stock Feb 26
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (Ruxolitinib) as A Treatment for Patients with Chronic Graft-Versus-Host Disease Feb 23
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis Feb 20
Revenue beats expectations Feb 11
Full year 2020 earnings released: US$1.36 loss per share (vs US$2.08 profit in FY 2019) Feb 11
Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement Jan 31 Hissedar Getirileri INCY * MX Biotechs MX Pazar 7D 0% 0% 0% 1Y n/a 0% 0%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: INCY * un MX Biotechs sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Getiri vs Piyasa: INCY * un MX Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Fiyat Oynaklığı Is INCY *'s price volatile compared to industry and market? INCY * volatility INCY * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
İstikrarlı Hisse Senedi Fiyatı: INCY * hisse senedi fiyatı, son 3 ayda MX piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: INCY * 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri .
Şirket Hakkında Bir biyofarmasötik şirketi olan Incyte Corporation, Amerika Birleşik Devletleri'nde ve uluslararası alanda hematoloji/onkoloji, inflamasyon ve otoimmünite alanlarına yönelik terapötiklerin keşfi, geliştirilmesi ve ticarileştirilmesi faaliyetlerini yürütmektedir. Şirket, orta veya yüksek riskli miyelofibroz, polisitemi vera ve steroide dirençli akut graft-versus-host hastalığının tedavisi için JAKAFI (ruxolitinib) sunmaktadır; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) relaps veya refrakter diffüz büyük B hücreli lenfoma için; PEMAZYRE (pemigatinib), sıvı ve solid tümör tiplerinde onkojenik sürücüler olarak hareket eden bir fibroblast büyüme faktörü reseptör kinaz inhibitörü; Kronik miyeloid lösemi ve Philadelphia kromozomu pozitif akut lenfoblastik lösemiyi tedavi etmek için ICLUSIG (ponatinib); ve metastatik veya tekrarlayan lokal olarak ilerlemiş Merkel hücreli karsinomlu yetişkinleri tedavi etmek için ZYNYZ (retifanlimab-dlwr) ve atopik dermatit tedavisi için OPZELURA krem. Klinik aşamadaki ürünleri arasında, anal kanalın skuamöz hücreli karsinomu ve küçük hücreli dışı akciğer kanseri için Faz 3 klinik çalışmalar altındaki retifanlimab; kronik GVHD'li hastalar için bir tedavi olarak geliştirilen Faz 2 altındaki bir anti-CSF-1R monoklonal antikoru olan aksatilimab; onkogenezi inhibe etmek için INCA033989; hastalık modifiye edici bir terapötik olarak geliştirilen INCB160058 ve solid tümörlerin tedavisi için INCB99280 ve INCB99318 bulunmaktadır.
Daha fazla göster Incyte Corporation Temel Bilgiler Özeti Incyte'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? INCY * temel i̇stati̇sti̇kler Piyasa değeri Mex$290.30b Kazançlar(TTM ) Mex$673.81m Gelir(TTM ) Mex$84.55b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) INCY * gelir tablosu (TTM ) Gelir US$4.08b Gelir Maliyeti US$2.88b Brüt Kâr US$1.20b Diğer Giderler US$1.16b Kazançlar US$32.48m
Son Raporlanan Kazançlar
Sep 30, 2024
Sonraki Kazanç Tarihi
Feb 10, 2025
Hisse başına kazanç (EPS) 0.17 Brüt Marj 29.33% Net Kâr Marjı 0.80% Borç/Özkaynak Oranı 0%
INCY * uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/28 10:20 Gün Sonu Hisse Fiyatı 2024/10/31 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Incyte Corporation 54 Bu analistlerden 23, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Jasper Hellweg Argus Research Company Thomas Russo Baird Ishan Majumdar Baptista Research
Göster 51 daha fazla analist 
